Preclinical outsourcing to grow 20% in 2016 says new report

By Gareth Macdonald

- Last updated on GMT

Preclinical outsourcing to grow 20% in 2016 says new report

Related tags Drug discovery Pharmaceutical industry Clinical trial Pharmacology

More drug discovery work will be outsourced this year according to a report which suggests pharmaceutical industry desire to reduce the risk of failure and cut costs persists.

The value of drug discovery work outsourced to contract research organisations (CRO) will increase 20% year-on-year to $21bn (€18.5bn) this year according to Kalorama Information.

Study author Anne Anscomb said the increase is part of a longer term trend, suggesting that “Over the next 4-5 years, it is predicted that almost half of the drug discovery research will be contracted to CROs​.”

"Thus, outsourcing drug discovery remains an important strategic imperative for pharmaceutical and biotechnology companies."​ 

In addition to drug industry desire for higher returns for R&D investment, Anscomb  also suggested geographic expansion of the pharmaceutical market will increase the amount of work outsourced.

"As more pharmaceutical companies from emerging countries become major players in the pharmaceutical industry, and multinational pharmaceutical companies expand into emerging countries, the global demand for drug discovery services will continue to expand this rapidly evolving market​."

The growth of the drug discovery outsourcing market will provide CROs with both an opportunity and a challenge according to Anscomb, who said contractors with the ability to invest in the latest technologies will be best placed to capitalize.

Related topics Preclinical Research Preclinical

Related news

Show more

Related products

show more

The Complexities of Ophthalmic Drug Development

The Complexities of Ophthalmic Drug Development

Altasciences | 04-Oct-2022 | Technical / White Paper

Ophthalmic drug development comes with a unique set of challenges that can be mitigated by working with an end-to-end solution provider with regulatory...

Strategic Approach to Immunogenicity Assessment

Strategic Approach to Immunogenicity Assessment

Altasciences | 17-May-2022 | Technical / White Paper

In this issue of The Altascientist we provide a detailed overview on the different goals and challenges that are presented by the validation of immunogenicity...

Clear Guidelines for IND/CTA

Clear Guidelines for IND/CTA

Altasciences | 24-Feb-2022 | Technical / White Paper

There are many challenges associated with early drug discovery and development. Advancing your best candidate for regulatory submissions requires a careful...

Follow us


View more